In males, where IRF5 strongly correlates with insulin resistance and metabolic dysfunction, therapeutic approaches that target IRF5 directly or modulate its upstream signaling pathways (e.g., TLR–MyD88–IRAK1) may help mitigate obesity-associated metabolic impairment. This evidence concerns the gene IRF5 and obesity due to melanocortin 4 receptor deficiency.